



HW

Attorney Docket No.: 6279.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Henrik Sonderskov Klint & Yoshio Higaki

Serial No.: 10/665,268

Group Art Unit: 3763

Filed: September 18, 2003

Examiner: Desanto, Matthew F.

For: Needle Cannula, A Method of Producing A Needle Cannula and Use of a Needle Cannula

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **February 28, 2006**

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)



Attorney Docket No.: 6279.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Henrik Sonderskov Klint & Yoshio Higaki

Application No.: 10/665,268

Group Art Unit: 3763

Filed: September 18, 2003

Examiner: Desanto, Matthew F.

For: Needle Cannula, A Method of Producing A Needle Cannula and Use of a Needle Cannula

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. SU 641965
2. SU 143202
3. US 4781691
4. SU 1764659
5. DE 3428711

03/07/2006 EHAILE1 00000044 141447 10665268

01 FC:1806 180.00 DA

Attorney Docket No.: 6279.220-US
Application No.: 10/665,268
Filed: September 18, 2003
Inventors: Klint et al.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: February 28, 2006



Marc A. Began, Reg. No. 48,829
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Group 3763

[illegible][illegible][illegible]

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.